vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Civeo Corp (CVEO). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $161.6M, roughly 1.8× Civeo Corp). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -4.0%, a 100.3% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 7.1%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -1.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
ACAD vs CVEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $161.6M |
| Net Profit | $273.6M | $-6.5M |
| Gross Margin | 90.8% | 22.7% |
| Operating Margin | 6.1% | -0.1% |
| Net Margin | 96.3% | -4.0% |
| Revenue YoY | 9.4% | 7.1% |
| Net Profit YoY | 90.3% | 58.1% |
| EPS (diluted) | $1.61 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $161.6M | ||
| Q3 25 | $278.6M | $170.5M | ||
| Q2 25 | $264.6M | $162.7M | ||
| Q1 25 | $244.3M | $144.0M | ||
| Q4 24 | $259.6M | $151.0M | ||
| Q3 24 | $250.4M | $176.3M | ||
| Q2 24 | $242.0M | $188.7M | ||
| Q1 24 | $205.8M | $166.1M |
| Q4 25 | $273.6M | $-6.5M | ||
| Q3 25 | $71.8M | $-455.0K | ||
| Q2 25 | $26.7M | $-3.3M | ||
| Q1 25 | $19.0M | $-9.8M | ||
| Q4 24 | $143.7M | $-15.4M | ||
| Q3 24 | $32.8M | $-5.1M | ||
| Q2 24 | $33.4M | $8.2M | ||
| Q1 24 | $16.6M | $-5.1M |
| Q4 25 | 90.8% | 22.7% | ||
| Q3 25 | 92.2% | 25.7% | ||
| Q2 25 | 92.2% | 25.3% | ||
| Q1 25 | 91.7% | 20.4% | ||
| Q4 24 | 91.6% | 18.6% | ||
| Q3 24 | 92.5% | 21.4% | ||
| Q2 24 | 92.5% | 25.4% | ||
| Q1 24 | 88.8% | 21.5% |
| Q4 25 | 6.1% | -0.1% | ||
| Q3 25 | 12.8% | 4.1% | ||
| Q2 25 | 12.2% | 1.7% | ||
| Q1 25 | 7.9% | -3.8% | ||
| Q4 24 | 59.1% | -6.7% | ||
| Q3 24 | 12.6% | 0.0% | ||
| Q2 24 | 12.6% | 6.9% | ||
| Q1 24 | 7.4% | -1.1% |
| Q4 25 | 96.3% | -4.0% | ||
| Q3 25 | 25.8% | -0.3% | ||
| Q2 25 | 10.1% | -2.0% | ||
| Q1 25 | 7.8% | -6.8% | ||
| Q4 24 | 55.4% | -10.2% | ||
| Q3 24 | 13.1% | -2.9% | ||
| Q2 24 | 13.8% | 4.4% | ||
| Q1 24 | 8.0% | -3.1% |
| Q4 25 | $1.61 | $-0.58 | ||
| Q3 25 | $0.42 | $-0.04 | ||
| Q2 25 | $0.16 | $-0.25 | ||
| Q1 25 | $0.11 | $-0.72 | ||
| Q4 24 | $0.86 | $-1.04 | ||
| Q3 24 | $0.20 | $-0.36 | ||
| Q2 24 | $0.20 | $0.56 | ||
| Q1 24 | $0.10 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $14.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $174.4M |
| Total Assets | $1.6B | $477.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $14.4M | ||
| Q3 25 | $258.0M | $12.0M | ||
| Q2 25 | $253.6M | $14.6M | ||
| Q1 25 | $217.7M | $28.4M | ||
| Q4 24 | $319.6M | $5.2M | ||
| Q3 24 | $155.1M | $17.9M | ||
| Q2 24 | $177.1M | $7.4M | ||
| Q1 24 | $204.7M | $16.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $174.4M | ||
| Q3 25 | $917.3M | $182.5M | ||
| Q2 25 | $822.4M | $209.4M | ||
| Q1 25 | $765.2M | $220.7M | ||
| Q4 24 | $732.8M | $236.4M | ||
| Q3 24 | $577.2M | $282.2M | ||
| Q2 24 | $516.7M | $297.4M | ||
| Q1 24 | $464.0M | $297.4M |
| Q4 25 | $1.6B | $477.4M | ||
| Q3 25 | $1.3B | $491.1M | ||
| Q2 25 | $1.2B | $508.8M | ||
| Q1 25 | $1.1B | $423.8M | ||
| Q4 24 | $1.2B | $405.1M | ||
| Q3 24 | $976.9M | $477.6M | ||
| Q2 24 | $914.1M | $483.2M | ||
| Q1 24 | $855.1M | $513.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $19.3M |
| Free Cash FlowOCF − Capex | — | $14.5M |
| FCF MarginFCF / Revenue | — | 8.9% |
| Capex IntensityCapex / Revenue | — | 3.0% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $19.3M | ||
| Q3 25 | $74.3M | $13.8M | ||
| Q2 25 | $64.0M | $-2.3M | ||
| Q1 25 | $20.3M | $-8.4M | ||
| Q4 24 | $40.4M | $9.5M | ||
| Q3 24 | $63.2M | $35.7M | ||
| Q2 24 | $25.0M | $32.4M | ||
| Q1 24 | $29.1M | $6.0M |
| Q4 25 | — | $14.5M | ||
| Q3 25 | $73.9M | $8.2M | ||
| Q2 25 | — | $-6.8M | ||
| Q1 25 | — | $-13.7M | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | $63.2M | $28.2M | ||
| Q2 24 | — | $27.0M | ||
| Q1 24 | — | $372.0K |
| Q4 25 | — | 8.9% | ||
| Q3 25 | 26.5% | 4.8% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -9.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | 25.2% | 16.0% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | 0.1% | 3.3% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 0.0% | 4.2% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | 3.93× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CVEO
Segment breakdown not available.
